Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer

NCT03836157 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Study was not initiated.

Conditions

Endometrial Cancer
Endometrial Adenocarcinoma
Endometrial Serous Adenocarcinoma
Endometrial Clear Cell Adenocarcinoma

Interventions

DRUG: Mirvetuximab Soravtansine
DRUG: Bevacizumab

Sponsor

University of Oklahoma

Collaborators

[object Object]